Last reviewed · How we verify
concurrent chemotherapy with docetaxel
Docetaxel works by inhibiting microtubule dynamics, thereby inducing apoptosis in cancer cells.
Docetaxel works by inhibiting microtubule dynamics, thereby inducing apoptosis in cancer cells. Used for Non-small cell lung cancer, Breast cancer, Prostate cancer.
At a glance
| Generic name | concurrent chemotherapy with docetaxel |
|---|---|
| Also known as | docetaxel |
| Sponsor | Air Force Military Medical University, China |
| Drug class | Taxane |
| Target | Microtubules |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Docetaxel binds to tubulin and prevents the formation of microtubules, which are essential for cell division. This leads to cell cycle arrest and apoptosis in rapidly dividing cancer cells. The exact mechanism of action is not fully understood, but it is thought to involve the inhibition of microtubule dynamics and the induction of apoptosis.
Approved indications
- Non-small cell lung cancer
- Breast cancer
- Prostate cancer
- Ovarian cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Fatigue
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Mucositis
- Neuropathy
Key clinical trials
- Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy (PHASE2)
- Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC (PHASE2)
- Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer (PHASE2, PHASE3)
- Partial Irradiation and Sequential vs. Concurrent Chemo Early Breast Cancer (NA)
- Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal or Gastroesophageal Junction Adenocarcinoma (PHASE2)
- Phase II Exploratory Study of Toripalimab Combined With SBRT in HER2-Negative Breast Cancer Patients With Insensitivity to Neoadjuvant Chemotherapy (PHASE2)
- Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC) (PHASE2)
- A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal Carcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: